NASDAQ: PRMEPrime Medicine Inc Stock
$3.91-0.07 (-1.76%)
Updated Sep 19, 2024
PRME Price
$3.91
Fair Value Price
$0.31
Market Cap
$469.32M
52 Week Low
$3.47
52 Week High
$11.51
P/E
-1.8x
P/B
2.39x
P/S
1,036.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$591.00k
Earnings
-$217.44M
Gross Margin
100%
Operating Margin
-36,809.98%
Profit Margin
-36,791.7%
Debt to Equity
0.32
Operating Cash Flow
-$196M
Beta
1.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRME Overview
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRME scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRME ($3.91) is overvalued by 1,173% relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PRME ($3.91) is not significantly undervalued (1,173%) relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PRME is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRME due diligence checks available for Premium users.
Be the first to know about important PRME news, forecast changes, insider trades & much more!
PRME News
Valuation
PRME fair value
Fair Value of PRME stock based on Discounted Cash Flow (DCF)
Price
$3.91
Fair Value
$0.31
Overvalued by
1,173.00%
PRME ($3.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRME ($3.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRME is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRME price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.8x
Industry
-135.85x
Market
25.52x
PRME price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.39x
Industry
6.51x
PRME is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRME's financial health
Profit margin
Revenue
$0.0
Net Income
-$55.3M
Profit Margin
0%
PRME's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRME's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$259.7M
Liabilities
$63.1M
Debt to equity
0.32
PRME's short-term assets ($170.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRME's short-term assets ($170.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRME's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.5M
Investing
$6.9M
Financing
$35.0k
PRME's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRME vs Biotech Stocks
Prime Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.